Novo Nordisk India unveils oral Semaglutide to treat diabetes

Published On 2022-01-25 12:23 GMT   |   Update On 2022-01-25 12:23 GMT
Advertisement

Drug firm Novo Nordisk India on Thursday said it has launched a first of its kind diabetes treatment medication in the country. The company said it has introduced the world's first and only oral semaglutide, a game-changer in diabetes management.

Semaglutide, a GLP-1 receptor analogue (GLP-1 RA) - one of the drug classes to treat diabetes, till now was available only in the form of injections and this is the first time such medication has been developed in an oral form.

For more information, check out the full story on the link below: 

First: Novo Nordisk India launches oral Semaglutide for diabetes treatment

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News